T. Rowe Price Group

Nuro, Inc. is a technology company established in 2016 and headquartered in Mountain View, California. The company specializes in manufacturing self-driving vehicles specifically designed for local goods transportation. Nuro's autonomous delivery service enhances local commerce by enabling merchants to efficiently deliver a wide range of products, including food and pharmaceuticals, directly to customers. Their fleet of electric, fully autonomous vehicles aims to provide quick, affordable, and safe delivery options, thereby transforming the logistics of local deliveries.

Arbor Biotechnologies, Inc., founded in 2016 and based in Cambridge, Massachusetts, operates within the biotechnology sector, focusing on bio-discovery and human diagnostic development. The company utilizes a range of advanced technologies, including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, to facilitate the discovery of proteins aimed at enhancing human health and sustainability. Arbor's proprietary genomic tools leverage AI and machine learning to analyze genomic sequence data, thereby improving the efficiency of developing curative treatments for genetic diseases. These innovations enable drug developers to replace entire genes and precisely correct mutations, ultimately addressing previously untreatable genetic conditions.

Epirus, Inc. is a company focused on developing advanced defense technologies that utilize artificial intelligence and directed energy systems. Based in Hawthorne, California, it specializes in solid-state, software-defined high-power microwave systems designed to counter unmanned aircraft and other asymmetric threats. The company's flagship product, ELECTROMAGNETIC PULSE, functions as a drone countermeasure by delivering multiple beams simultaneously, effectively disrupting and neutralizing aerial threats. Additionally, Epirus employs AI and computer vision to enhance its capabilities in detecting and tracking various targets of interest. Founded in 2018, Epirus aims to provide innovative solutions for both national security and commercial applications, optimizing power management and efficiency in electronic warfare scenarios.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

SandboxAQ develops artificial intelligence and quantum technology products aimed at addressing complex business and scientific challenges. The company specializes in creating software that combines knowledge from multiple disciplines, including physics, computer science, and mathematics, to produce Large Quantitative Models (LQMs) and AI sensing applications. These innovations focus on delivering practical solutions in industries such as financial services, healthcare, and telecommunications. By enabling cross-disciplinary collaboration, SandboxAQ's technology addresses real-world computational challenges, facilitating advancements in areas like life sciences, navigation, and cybersecurity.

nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.

Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.

Lightmatter specializes in developing photonic chips that leverage light for data processing and communication, significantly enhancing the speed and efficiency of artificial intelligence computations. By utilizing integrated optical technology, the company designs processors that accelerate key operations in neural networks through programmable photonic elements, which are fabricated alongside traditional transistors. This innovative approach allows for improved performance in applications such as image recognition and natural language processing while maintaining low power consumption. Lightmatter's technology primarily serves sectors including artificial intelligence, cloud computing, and telecommunications, positioning the company as a leader in light-based computing solutions.

Form Energy, Inc. specializes in the development of long-duration energy storage systems aimed at enhancing the reliability of renewable energy sources such as wind and solar. Founded in 2017 and based in Somerville, Massachusetts, the company focuses on creating low-cost battery systems, including its innovative iron-air battery technology, which allows for energy storage over extended periods. This capability enables the dispatch of renewable energy throughout the year, effectively replacing traditional fossil fuel-based generation and contributing to the decarbonization of the electric grid. Additionally, Form Energy offers Formware, a capacity expansion software tool designed to optimize energy management. The company's technological advancements are rooted in research from MIT and are supported by various investors committed to sustainable energy solutions.

KoBold Metals operates as an AI-powered mineral exploration company focused on discovering materials essential for the electric vehicle and renewable energy sectors. The company utilizes advanced software that aggregates and structures extensive scientific datasets, including geochemical, geophysical, and geological information. By applying various analytical techniques such as ensemble machine learning and computer vision, KoBold predicts subsurface compositions in a statistically valid manner. This innovative approach enhances the exploration efficiency for mineral resources, particularly cobalt, which is crucial for the electric vehicle industry. By merging ore-deposit science with big data and scientific computing, KoBold Metals aims to identify new sources of cobalt and support the sustainable supply chain for emerging technologies.

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

Clio is a provider of a cloud-based practice management platform tailored specifically for solo practitioners and small law firms. Its suite of web-based tools streamlines essential functions such as client management, billing, administration, and communication. By enhancing these day-to-day processes, Clio enables legal professionals to efficiently manage their cases and improve client collaboration. The platform is designed to simplify the complexities of legal practice, making it an essential resource for modern law firms seeking to optimize their operations.

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.

PolicyBazaar Insurance Brokers Private Limited is an online platform based in Gurugram, India, specializing in insurance services. Founded in 2014, the company offers a wide range of insurance products, including life, health, car, two-wheeler, travel, and home insurance. The platform features a comparison portal and mobile application that allow users to compare different insurance plans based on coverage, premiums, benefits, and exclusions. This enables consumers to make informed decisions about their insurance needs. Additionally, PolicyBazaar provides tools and calculators for users to estimate their insurance requirements and premiums. The company primarily generates revenue from its insurance brokerage services, while also aiming to enhance financial awareness in India regarding the implications of death, disease, and damage.

Sila is a battery materials company founded in 2011 and headquartered in California, United States. It specializes in manufacturing energy-dense lithium-ion batteries designed for electric vehicles and consumer electronics. Sila collaborates with automotive original equipment manufacturers (OEMs) to accelerate product development and partners with battery manufacturers to enhance commercial cell production. The company focuses on providing advanced battery materials that improve energy storage capabilities, enabling the production of small, light, and long-lasting devices. By offering superior performance and quality control, Sila aims to facilitate the mass adoption of affordable, long-range electric vehicles while maintaining safety and cycle life standards.

Kardium is a technology pioneer working to advance medical device technology in the diagnosis and treatment of atrial fibrillation. Kardium was founded in 2007 and has built an outstanding team with a track record of excellence in medicine, business, and engineering. We have hired the best engineers, medical researchers and production staff and have been working with a team of top medical advisors to develop the Globe mapping and ablation system. The Globe system has been entirely developed by the team at Kardium and provides a complete system to assist in the diagnosis and treatment of atrial fibrillation. Kardium is based in Vancouver, Canada, and has consistently ranked as one of the top companies to work for in British Columbia.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

BrightView Holdings Inc is a prominent provider of commercial landscaping services in the United States, employing over 18,000 individuals. The company specializes in a wide range of services, including landscape maintenance, enhancements, tree care, and landscape development. BrightView operates through two main segments: Maintenance Services and Development Services. Maintenance Services are primarily self-performed via a national branch network, focusing on route-based operations, while Development Services involve the design, coordination, and installation of landscapes for notable corporate, athletic, and university complexes. Serving a diverse clientele that includes corporate properties, public parks, healthcare facilities, educational institutions, and golf courses, BrightView is committed to creating exceptional landscapes that enhance the quality of life in the communities it serves.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Lambda is a deep-learning infrastructure company that specializes in providing computation resources to enhance human progress. It offers a cloud computing platform tailored for large-scale artificial intelligence training and inference, with a focus on simplifying the deployment of deep learning models. The company's product lineup includes pre-configured servers and workstations equipped with popular machine learning frameworks, allowing clients to efficiently train complex models for various applications, such as natural language processing and drug discovery. Lambda enables AI engineers to securely and cost-effectively develop, test, and deploy AI products at scale, with solutions ranging from on-premises GPU hardware to cloud-hosted GPUs.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Lilac Solutions, Inc. is a mining technology company focused on lithium extraction, providing innovative technology and services to lithium producers. The company specializes in ion exchange beads and continuous brine processing systems, which enable the efficient production of high-purity lithium solutions from various brine resources. This technology, grounded in ion-exchange theory, allows lithium producers to enhance project development, improve lithium recovery rates, and optimize operational efficiency while also minimizing costs and environmental impact. Lilac Solutions serves industries such as electric vehicles and renewable energy storage. Incorporated in 2015, the company is headquartered in Oakland, California.

Odyssey Therapeutics is a biotechnology company focused on developing next-generation immunomodulators and oncology drugs. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, identifying promising targets while reducing the likelihood of failure during development. Odyssey Therapeutics is committed to advancing the field of drug discovery and expediting clinical development, ultimately contributing to the creation of more effective precision medicines for the healthcare industry.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

You have always been told “they can’t do it“ or “it’s going to take a year.“ Legacy technology should not be your obstacle; now you can transform development processes that would take years into hours. They don’t wrap old technology with an API layer. They create everything as an API, so they can help you innovate faster. Their engineers, ex-bankers and fintech-savvy leaders are pursuing an ambitious goal: to change the future of banking with their solutions. They are headquartered in Wilmington, NC, with an office in Austin, TX.

Stash develops a personal finance application to combine banking, investing, and advice into one platform. Its application's services include personal investment accounts, retirement accounts, and custodial accounts for minors. It also provides the option to buy fractional shares of stocks, bonds, and funds with no add-on trading commissions to help users save small sums of money and make micro-investments.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Databricks Inc. offers a unified data analytics cloud platform that simplifies data engineering and supports collaborative data science. Its core product, Databricks, enables organizations to process and analyze large datasets efficiently, leveraging tools like Apache Spark. The platform is designed for real-time experimentation and robust deployment of production applications, catering to developers and data scientists. Additionally, Databricks provides Databricks Delta, a data management system that combines the scalability of a data warehouse with low-latency streaming capabilities. The company also offers MLflow for managing the machine learning lifecycle and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including healthcare, finance, manufacturing, and telecommunications. Founded in 2013 and headquartered in San Francisco, with additional offices in London, Amsterdam, and Bengaluru, Databricks has established strategic partnerships to enhance its offerings and foster innovation in data and AI technologies.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

Redwood Materials, Inc. specializes in the development of innovative recycling processes aimed at creating circular supply chains for lithium-ion batteries and other electronic products. Founded by JB Straubel and based in Carson City, Nevada, the company focuses on recovering valuable materials such as lithium, nickel, copper, cobalt, and other metals from end-of-life batteries and electronics. Redwood receives approximately 10 GWh of batteries annually for recycling, which are refined and remanufactured into essential anode and cathode materials. The company is actively working to scale its production capacity to 100 GWh annually by 2025, sufficient to produce over one million electric vehicles each year. By emphasizing sustainable practices, Redwood Materials aims to reduce the environmental impact of battery production and support the growth of the electric vehicle and renewable energy storage markets.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

Genesis Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing small molecule drug candidates aimed at treating patients with severe and debilitating disorders. Established in 2019, the company harnesses a proprietary artificial intelligence platform that employs advanced deep neural networks and biophysical simulation techniques to enhance drug discovery and molecular design. By combining these innovative technologies with a scalable computing infrastructure, Genesis Therapeutics aims to improve the efficiency and accuracy of molecular research. This approach not only facilitates the generation and analysis of novel drug candidates but also holds the potential to significantly advance clinical outcomes in the medical community.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

KoBold Metals operates as an AI-powered mineral exploration company focused on discovering materials essential for the electric vehicle and renewable energy sectors. The company utilizes advanced software that aggregates and structures extensive scientific datasets, including geochemical, geophysical, and geological information. By applying various analytical techniques such as ensemble machine learning and computer vision, KoBold predicts subsurface compositions in a statistically valid manner. This innovative approach enhances the exploration efficiency for mineral resources, particularly cobalt, which is crucial for the electric vehicle industry. By merging ore-deposit science with big data and scientific computing, KoBold Metals aims to identify new sources of cobalt and support the sustainable supply chain for emerging technologies.

They founded their company on the belief that there is a better way to serve retirees or people getting ready to retire—one that is smarter and more personalized.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

VerAI Discoveries is an AI-driven mineral asset portfolio company that leverages artificial intelligence and machine learning to identify concealed mineral deposits. By concentrating on underexplored covered terrain in prime mining jurisdictions, VerAI enhances the likelihood of discovering significant mineral deposits while reducing economic risk. The company collaborates with leading industry investors and explorers to develop a global portfolio focused on base and precious metals, thereby unlocking value and contributing to the global supply of critical minerals. Through its innovative platform, VerAI aims to transform the mineral exploration industry by uncovering unique signatures of existing deposits within complex datasets.

Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

Mirion Technologies is a provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Many of the company's end markets are characterized by the need to meet rigorous regulatory standards, design qualifications and operating requirements.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Jetti Resources is a company based in Vancouver, Canada, that specializes in developing hydrometallurgical technology for the extraction of metals from mineral ores. Founded in 2014, Jetti focuses primarily on extracting copper from low-grade primary sulfides, including chalcopyrite, which is the most abundant copper mineral ore. The company has developed a proprietary catalytic technology that enhances copper recovery from vast quantities of ore, addressing significant challenges in mineral processing. This technology integrates with existing heap leaching methods and downstream operations, allowing industrial clients to improve copper yields in a cost-effective and environmentally sustainable manner. Additionally, Jetti's technology is applicable for the extraction of zinc and nickel from sulfide ores, further diversifying its capabilities in mineral processing.

Celonis specializes in execution management, focusing on helping companies optimize their business processes through its advanced process mining technology. The company's core offering, the Celonis Execution Management System (EMS), provides a comprehensive suite of tools and applications that assist organizations in managing various aspects of execution, from analytics and strategy to planning, management, and automation. By leveraging its unique software solutions, Celonis enables businesses across industries such as production, human resources, and logistics to enhance productivity, improve process transparency, and increase operational efficiency. The emphasis on analyzing and optimizing online business processes positions Celonis as a key player in the field of management consultancy and automation.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

YuLife is a London-based insurance company founded in 2016 that focuses on promoting well-being through its innovative insurance platform. By integrating gamification and behavioral science, YuLife offers life and medical insurance plans that incentivize healthy living. Users are encouraged to engage in activities such as walking and meditation, earning rewards like air miles, vouchers, and gift cards as they pursue a healthier lifestyle. This approach not only supports individual wellness but also helps businesses ensure their employees are insured while fostering a culture of health and motivation. YuLife aims to transform financial products into a force for good, making everyday wellness accessible to all.

Flexe, Inc. operates a cloud-based marketplace that connects organizations seeking additional warehousing and fulfillment services with those that have surplus capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics solutions, including eCommerce fulfillment, retail distribution, and same-day delivery. Flexe's platform addresses the challenges of inventory overflow and fulfillment needs by creating an open logistics network, allowing clients such as retailers, wholesalers, manufacturers, and logistics companies to optimize their distribution capabilities. By integrating technology and flexible economic models, Flexe enables its customers to enhance their operational efficiency and respond swiftly to market demands.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Odyssey Therapeutics is a biotechnology company focused on developing next-generation immunomodulators and oncology drugs. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, identifying promising targets while reducing the likelihood of failure during development. Odyssey Therapeutics is committed to advancing the field of drug discovery and expediting clinical development, ultimately contributing to the creation of more effective precision medicines for the healthcare industry.

Convoy, Inc. operates an online marketplace that provides digital freight network services, enabling users to book local and regional trucks on demand for transporting goods, ranging from single pallets to full truckloads. The company offers a mobile application that features real-time shipment tracking, status updates, and ensures on-time deliveries. Founded in 2015 and based in Seattle, Washington, Convoy aims to enhance efficiency in the trucking industry, which is valued at $800 billion and is responsible for significant carbon emissions from empty trucks. By utilizing technology and data, Convoy addresses issues of waste and inefficiency, ultimately saving money for shippers, increasing earnings for drivers, and reducing carbon waste. The platform facilitates instant quotations, online bookings, automated loading suggestions, and online payments, all of which contribute to improved operational efficiency and cost reduction for clients.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Cross River Bank, based in Fort Lee, New Jersey, provides a range of personal and corporate banking products and services to individuals and businesses across the United States. Its offerings include checking and savings accounts, direct lending, and commercial real estate loans for various property types in the New York, New Jersey, and Connecticut areas. The bank has established partnerships with financial technology firms to create integrated solutions in marketplace lending and payment processing, emphasizing regulatory compliance and consumer protection. By leveraging innovative technologies, Cross River Bank aims to deliver responsible financial solutions that empower clients through secure, application programming interface-based banking platforms, encompassing lending, payments, and banking-as-a-service offerings. Founded in 2008, Cross River Bank operates as a subsidiary of CRB Group, Inc.

SandboxAQ develops artificial intelligence and quantum technology products aimed at addressing complex business and scientific challenges. The company specializes in creating software that combines knowledge from multiple disciplines, including physics, computer science, and mathematics, to produce Large Quantitative Models (LQMs) and AI sensing applications. These innovations focus on delivering practical solutions in industries such as financial services, healthcare, and telecommunications. By enabling cross-disciplinary collaboration, SandboxAQ's technology addresses real-world computational challenges, facilitating advancements in areas like life sciences, navigation, and cybersecurity.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.

Rigetti Computing is a full-stack quantum computing company that designs and manufactures quantum-integrated circuits, deploying them in low-temperature environments. The company develops proprietary control systems to execute quantum logic operations and has created software to integrate its quantum systems with existing cloud infrastructure. Rigetti's innovations include the industry's first multi-chip quantum processor, which enables scalability in quantum computing systems. The company focuses on practical applications of quantum computing, particularly in computational chemistry and machine learning, and offers the Forest platform, a comprehensive programming and execution environment for quantum and classical computing. Most of its revenue is generated from the United States.

CelLink Corporation is an innovative company focused on developing flexible conductive backplanes and circuits for power electronics, including applications in batteries, solar panels, light-emitting diodes, and wire harnessing. Founded in 2012 and based in Belmont, California, CelLink manufactures high-conductance, large-area flexible circuits designed to facilitate clean power transmission. Their products integrate essential components such as busing, fusing, and voltage and temperature monitoring into a single circuit, providing customers with efficient solutions for power and data transmission at competitive prices. By offering advanced technology in a growing market, CelLink aims to support the increasing demand for sustainable energy solutions.

Epirus, Inc. is a company focused on developing advanced defense technologies that utilize artificial intelligence and directed energy systems. Based in Hawthorne, California, it specializes in solid-state, software-defined high-power microwave systems designed to counter unmanned aircraft and other asymmetric threats. The company's flagship product, ELECTROMAGNETIC PULSE, functions as a drone countermeasure by delivering multiple beams simultaneously, effectively disrupting and neutralizing aerial threats. Additionally, Epirus employs AI and computer vision to enhance its capabilities in detecting and tracking various targets of interest. Founded in 2018, Epirus aims to provide innovative solutions for both national security and commercial applications, optimizing power management and efficiency in electronic warfare scenarios.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.

SalioGen Therapeutics is a biotechnology company focused on developing gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT), the company employs mammal-derived enzymes, known as Saliogase, to facilitate genome engineering. This innovative approach enables the delivery of any size gene through non-viral methods, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide durable, safe, and affordable treatments, potentially transforming the landscape of care for patients with genetic conditions and enhancing the efficiency of cell therapy and biologics manufacturing in the healthcare sector.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections. It utilizes modern reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is an oral antiviral designed to treat and prevent infections from SARS-CoV-2, the virus responsible for COVID-19. By reimagining the patient journey, Pardes aims to provide accessible and convenient treatment options for both adult and pediatric patients, ultimately striving to improve health outcomes and respond effectively to global health crises.

Airtable is a cloud-based software company that provides an online platform for creating and sharing relational databases. The platform is designed to democratize software creation, allowing users to build custom applications tailored to their needs without requiring coding expertise. Airtable facilitates the development of flexible checklists, the organization of collections or ideas, and the management of customer contacts. It also offers a diverse range of templates, covering areas such as home improvement and inventory management, which help users efficiently structure their projects and workflows.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.

Grab Holdings Inc. is a prominent online-to-offline service provider based in Singapore, focusing on mobile technology solutions for transportation across Southeast Asia. Founded in 2012 by Anthony Tan and Tan Hooi Lng, Grab integrates various transportation services through its platform, which includes offerings such as GrabTaxi, GrabCar, GrabHitch, GrabShare, GrabCoach, GrabShuttle, GrabShuttle Plus, GrabFamily, JustGrab, GrabNow, and GrabRental. The company operates in multiple countries, including Singapore, Indonesia, the Philippines, Malaysia, Thailand, Vietnam, and Myanmar. In addition to its headquarters in Singapore, Grab has offices in Seattle, Beijing, Bangalore, Jakarta, and Vietnam, further extending its reach and capabilities within the region.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Farmers Business Network, Inc. is an independent agricultural technology and commerce platform that connects farmers through a farmer-to-farmer network. It aims to enhance the economic viability of farms and promote sustainable practices. By leveraging data science, FBN provides agronomic insights, enabling farmers to make informed decisions regarding their crops and operations. The platform allows members to share information, purchase inputs directly from manufacturers, and navigate the market more effectively. Additionally, FBN assists farmers in selling their crops independently and offers various insurance options. With over 800 employees, Farmers Business Network supports members who collectively farm more than 80 million acres across the United States, Canada, and Australia, with headquarters in multiple locations including California, Illinois, South Dakota, Alberta, and Perth.

Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.

Arbor Biotechnologies, Inc., founded in 2016 and based in Cambridge, Massachusetts, operates within the biotechnology sector, focusing on bio-discovery and human diagnostic development. The company utilizes a range of advanced technologies, including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, to facilitate the discovery of proteins aimed at enhancing human health and sustainability. Arbor's proprietary genomic tools leverage AI and machine learning to analyze genomic sequence data, thereby improving the efficiency of developing curative treatments for genetic diseases. These innovations enable drug developers to replace entire genes and precisely correct mutations, ultimately addressing previously untreatable genetic conditions.

Color is a healthcare technology company that provides a comprehensive platform for managing large-scale health initiatives, including population genomics and COVID-19 testing. The company focuses on delivering equitable and accessible healthcare programs tailored for businesses, schools, and public health departments. By centralizing essential healthcare capabilities, Color addresses logistical challenges and enhances the delivery of preventive care. Its offerings facilitate a range of services, from testing and screening to treatment and referrals, thereby supporting clinical teams in effectively managing public health across diverse populations. Through its innovative model, Color aims to improve health outcomes and create sustainable revenue streams while ensuring that quality healthcare is available to all.

Socure Inc. specializes in digital identity verification solutions, utilizing artificial intelligence and machine learning to authenticate identities in real-time. Its flagship platform, Socure ID+, integrates data from various online and offline sources, including email, phone numbers, and social media, to streamline customer identification processes and ensure compliance with regulations such as know your customer (KYC) and anti-money laundering (AML). In addition to Socure ID+, the company offers tools like Aida, an AI-driven bot for real-time identity validation; Docv, a document verification solution; and Sigma Synthetic Fraud, which targets synthetic identity fraud. Serving a diverse clientele that includes software and financial firms, as well as integration partners and sponsor banks, Socure aims to eliminate identity fraud and enhance security for online transactions. Founded in 2012 and headquartered in New York, Socure has established strategic partnerships to expand its reach and effectiveness in the identity verification landscape.

Nextdoor, Inc. operates a social networking platform designed to facilitate local conversations and connections among neighbors. Founded in 2007 and headquartered in San Francisco, the company aims to cultivate a kinder, more connected world by enabling residents to engage with each other, local businesses, services, and community news. The platform includes features such as Help Map, which allows users to offer assistance to vulnerable neighbors, particularly during the Covid-19 pandemic. Nextdoor serves neighborhoods globally, including in the United States, the United Kingdom, Germany, France, and several other countries. The company is privately held and has received investment from notable firms, reinforcing its mission to foster real-world connections and community support.

Aurora Innovation develops advanced software and hardware products for self-driving vehicles, aiming to transform the movement of people and goods. Founded in 2016 and headquartered in Palo Alto, California, the company operates additional offices in the Bay Area, Bozeman, Pittsburgh, and Dallas. Its primary offering, the Aurora Driver, is a scalable self-driving system capable of operating various vehicle types, including freight-hauling trucks and ride-hailing passenger vehicles. This technology supports Aurora's driver-as-a-service products, Aurora Horizon and Aurora Connect, catering to trucking and ride-hailing sectors. By integrating rigorous engineering with applied machine learning, Aurora Innovation seeks to create a comprehensive transportation ecosystem that connects automakers, logistics services, and mobility providers.

Nuro, Inc. is a technology company established in 2016 and headquartered in Mountain View, California. The company specializes in manufacturing self-driving vehicles specifically designed for local goods transportation. Nuro's autonomous delivery service enhances local commerce by enabling merchants to efficiently deliver a wide range of products, including food and pharmaceuticals, directly to customers. Their fleet of electric, fully autonomous vehicles aims to provide quick, affordable, and safe delivery options, thereby transforming the logistics of local deliveries.

Rad Power Bikes LLC, based in Seattle, Washington, is a leading manufacturer and retailer of electric bicycles in North America. Founded in 2015, the company specializes in designing feature-rich e-bikes suitable for both on and off-road use, catering to a diverse range of consumer needs. In addition to its electric bikes, Rad Power Bikes offers a variety of accessories such as bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. The company operates on a direct-to-consumer model, selling its products primarily through online platforms, which allows it to provide affordable and accessible transportation solutions. With a rapidly expanding workforce exceeding 700 employees, Rad Power Bikes is committed to revolutionizing electric mobility and promoting energy-efficient transportation options.

Oak Hill Advisors L.P. is a privately owned investment manager based in New York, with additional offices in major cities across the globe. Founded in 1991, the firm specializes in alternative credit management, focusing on leveraged loans, high yield bonds, distressed securities, and structured products. Its investment activities target the North American and European markets, managing a diverse range of funds including distressed funds, credit hedge funds, and customized accounts. Oak Hill Advisors employs a fundamental value-oriented strategy, emphasizing credit analysis and active risk management. The firm typically invests between $5 million and $100 million in small to mid-sized companies, engaging in various investment strategies such as acquisitions, buyouts, and turnaround situations. It primarily seeks opportunities in sectors such as energy, natural resources, healthcare, and business services. The firm serves a global clientele, including pension funds, insurance companies, and family offices, and is registered as an investment adviser.

Trumid Financial LLC is a financial technology company focused on enhancing the electronic trading experience in the credit market. Established in 2014 and based in New York, Trumid operates the Trumid Market Center, an electronic trading network and market intelligence platform for corporate bonds. The company also provides Trumid Bond Stream, which delivers TRACE pricing data to traders, and Trumid Labs, which utilizes data science to manage trading networks and offer bond price lookup services. By combining advanced technology with market expertise, Trumid aims to improve efficiency and provide corporate bond market professionals with direct access to liquidity and valuable market insights, enabling informed trading decisions.

Honor is the largest senior care network and technology platform globally, dedicated to enhancing the quality of life for older adults and their families. Founded in 2014 in San Francisco by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg, the company aims to improve in-home care services for seniors. In 2021, Honor expanded its reach by acquiring Home Instead, which strengthened its network and introduced a relationship-based care model. The company combines workforce management and technology expertise with personalized care delivered through a network of third-party providers. This integrated approach allows older adults to receive reliable, transparent, and quality care, enabling them to live safely and comfortably in their own homes.

Coalition, Inc. specializes in providing insurance coverage and risk management tools aimed at mitigating cyber risk for a diverse range of industries, including healthcare, retail, technology, real estate, non-profits, and more. Founded in 2017 and headquartered in San Francisco, Coalition combines comprehensive insurance solutions with proactive cybersecurity tools. The company's Active Risk Platform offers features such as automated security alerts, threat intelligence, and expert guidance to enhance organizational resilience against cyber threats. Backed by prominent global insurers, Coalition operates in the United States and Canada, delivering its security products to businesses worldwide. By integrating risk assessment, security protection, and response strategies, Coalition helps organizations effectively manage and reduce their exposure to cyber-attacks.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Canva, Inc. is a graphic design software provider based in Surry Hills, Australia, established in 2012. The company operates an online platform that enables users to create a variety of visual content, including presentations and social media graphics, using an intuitive drag-and-drop interface. Canva offers a diverse library of layouts, images, photo filters, icons, and fonts, which allows users to personalize their designs without needing advanced software skills. Additionally, Canva provides a plug-in called Canva Button for third-party websites, facilitating graphic creation for their users. The platform serves a wide range of customers, including photographers, illustrators, and designers, with the goal of making design more accessible to everyone.

Snyk Ltd. is a software as a service company that provides a platform for identifying, fixing, and monitoring vulnerabilities in applications. Founded in 2015 and headquartered in London, with additional offices in Tel Aviv, Boston, and Ontario, Snyk offers a range of solutions tailored for developers and security teams. Its key products include Snyk Code, a developer-first static application security testing tool, and container vulnerability management for securing Docker images. The platform also supports application security management, licensing compliance, and infrastructure as code security, ensuring that all components of modern applications are secure. Snyk’s Developer Security Platform integrates seamlessly into developers' workflows, promoting collaboration between development and security teams. The company serves over 1,200 customers globally, including notable organizations like Google and Salesforce, and has formed a strategic partnership with Rapid7. Snyk is recognized for its contributions to enhancing application security in an increasingly digital landscape.

Checkr, Inc. is a technology company specializing in the background check industry. Founded in 2014 and headquartered in San Francisco, California, Checkr offers a range of screening services, including criminal record checks, driving checks, and identity verification. The company utilizes advanced technology, including artificial intelligence and machine learning, to deliver faster and more efficient background checks compared to traditional providers. Its platform not only enhances hiring transparency and fairness but also assists businesses in complying with regulations and improving operational efficiency. Checkr serves various sectors, including financial services, healthcare, retail, and technology, providing solutions that cater to the evolving needs of the workforce.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.

Databricks Inc. offers a unified data analytics cloud platform that simplifies data engineering and supports collaborative data science. Its core product, Databricks, enables organizations to process and analyze large datasets efficiently, leveraging tools like Apache Spark. The platform is designed for real-time experimentation and robust deployment of production applications, catering to developers and data scientists. Additionally, Databricks provides Databricks Delta, a data management system that combines the scalability of a data warehouse with low-latency streaming capabilities. The company also offers MLflow for managing the machine learning lifecycle and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including healthcare, finance, manufacturing, and telecommunications. Founded in 2013 and headquartered in San Francisco, with additional offices in London, Amsterdam, and Bengaluru, Databricks has established strategic partnerships to enhance its offerings and foster innovation in data and AI technologies.